Telotristat etiprate

Drug Profile

Telotristat etiprate

Alternative Names: LX 1032; LX 1606; LX1032 hippurate; LX1606 hippurate; Xermelo

Latest Information Update: 07 Dec 2016

Price : $50

At a glance

  • Originator Lexicon Pharmaceuticals
  • Developer Ipsen; Lexicon Pharmaceuticals
  • Class Pyrazoles; Pyrimidines; Small molecules
  • Mechanism of Action Serotonin modulators; Tryptophan hydroxylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant carcinoid syndrome
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Malignant carcinoid syndrome
  • New Molecular Entity Yes
  • Available For Licensing Yes - Gastrointestinal disorders

Highest Development Phases

  • Preregistration Malignant carcinoid syndrome
  • Discontinued Ulcerative colitis

Most Recent Events

  • 31 Oct 2016 Updated efficacy and adverse event data from a phase III trial in Carcinoid syndrome (Refractory metastatic disease) released by Lexicon Pharmaceuticals
  • 07 Oct 2016 Pooled adverse events data from two phase III trials (TELESTAR and TELECAST) in carcinoid syndrome presented at the 41st European Society for Medical Oncology Congress (ESMO - 2016)
  • 03 Oct 2016 Updated adverse events and efficacy data from a phase III trial in Carcinoid syndrome released by Lexicon Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top